Navigation Links
Immunotherapy-Based Provisional Patents Mark Significant Discovery
Date:3/31/2009

Quantum Immunologics announces the filing of two important provisional patent applications

TAMPA, Fla., March 31 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Florida-based company specializing in cancer immunotherapy, has recently filed two provisional patent applications relating to their work in cancer immunotherapy.

The company's research is focused on the use of the oncofetal antigen ("OFA"), or more specifically, iLRP - immature Laminin Receptor Protein, as a cancer immunogen (a cancer target against which the immune system is directed) found in many tumor cell lines or fetal tissue, but not found in normal mature tissue. This makes it a unique target for personalized anti-cancer therapy for multiple cancers. The company is currently conducting clinical trials using OFA/iLRP as an immunogen in Stage IV breast cancer patients. The FDA-approved trial involves using the body's own immune cells, i.e., the dendritic cells, to recognize OFA/iLRP as a foreign protein and to have them direct the immune system against the cancer cells.

The first patent application describes the discovery of protein sequences, known as a peptides, found on the OFA/iLRP protein that are thought to be more immunogenic and more specific than the OFA/iLRP protein as a whole. With the discovery of these sequences, QI believes that dendritic cell recognition of the foreign cancer protein can be more efficient and specific, and will therefore result in a more effective immunotherapy treatment against malignancy. Additionally, QI researchers believe that it may also be possible to someday inoculate patients directly with the peptides as a direct immunogen to create immunity against cancer without the use of dendritic cells.

The second patent relates to antibodies discovered against these specific peptides. Antibodies are proteins made by the B cells of the body's immune system to aid in the recognition and destruction of foreign materials including cancer cells. Because they have a strong affinity for specific regions in proteins found on cancer cells (OFA/iLRP peptides), these antibodies have diagnostic and therapeutic uses. From a diagnostic standpoint, tests can be created to diagnose the presence or location of cancer in serum or in tissue by the addition of marker substances to the antibodies. From a therapeutic standpoint, these antibodies, once prepared for human use, may possibly be used as a therapy against the cancer (passive immunity), or if joined with materials toxic to cancer cells or by altering the structure of the antibody, provide a more effective and direct therapy to destroy cancer cells while sparing normal tissue.

With these new discoveries, QI has improved its pipeline and intellectual property portfolio and hopes to promote its goals of providing effective anti-cancer therapy with minimal side effects, and to design effective methods for the earlier detection of cancers. Research is presently being planned and conducted to advance these discoveries to promote their use within clinical settings.

About Quantum Immunologics

Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives. QI is currently involved in Phase I/II FDA clinical trials in Mobile, Alabama, for patients with stage IV breast cancer. For more information about the company, visit http://www.quantumimmunologics.com

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    Contact:

    Barry Rooth
    Corporate Affairs
    219-801-2299

    Or

    Timothy Schwiers
    Investor Relations
    813-849-7859

    Quantum Immunologics, Inc.
    3000 Bayport Dr. Suite 910
    PO Box 20727
    Tampa, FL 33623-0727

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
2. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
3. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
4. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
5. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
6. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
7. U.S. PTO Reexamining Lumenis Patents
8. Mercury Therapeutics Patents Filed
9. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
10. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
11. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):